Spruce Biosciences, Inc. (SPRB)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $40.49
- As of
Kresmion compiles this page from SPRB's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
SPRUCE BIOSCIENCES, INC. (SPRB): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-09.
See the full SPRB dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for SPRB on one page. Preview it with sample data, then open it live with a free account.
Preview the SPRB dossierActive events for SPRB
- mediumEarnings below estimates
Q3-2026: Missed consensus by 47.0%, EPS $-8.51 vs $-5.7893 estimate
- medium13F: new position
Point72 Asset Management, L.P. new position in SPRB
- medium13F: new position
RENAISSANCE TECHNOLOGIES LLC new position in SPRB
- mediumEarnings below estimates
Q2-2026: Missed consensus by 12.9%, EPS $-6.68 vs $-5.9177 estimate
- medium13F: new position
MILLENNIUM MANAGEMENT LLC new position in SPRB
FREE, NO ACCOUNT
Every event on SPRB, as it fires
You are seeing 5 of 7 events recorded on SPRB since 2026-05-30.
The five above landed across 4 days. The other 2 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, SPRB
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
Going concern statement
SPRB's 10-Q filed Nov 9, 2026 states:
Accordingly, there is substantial doubt about the Company's ability to continue as a going concern for at least 12 months following the issuance date of these condensed consolidated financial statements.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on SPRB
SPRB against its peers
SPRB's return on equity of -91.7% ranks in the 39th percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-10-31 and 2025-12-31.
| Metric | SPRB | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 0.0 USD | 29.2M USD | 9 | 10 |
| Operating margin | n/a | -279.5% | n/a | 9 |
| Net margin | n/a | -229.6% | n/a | 9 |
| Return on equity | -91.7% | -82.9% | 39 | 18 |
| 1 year | -61.9% | -34.9% | 24 | 22 |
Peers (24): FHTX, PYPD, ENGN, PDSB, ZURA, IMUX, LENZ, CLLS, CUE, ADAG, NERV, CNTN, MOLN, CMPX, XGN, MSLE, MGNX, MENS, NTHI, ANIX, OKUR, ALXO, VYGR, ARMP. Left out: RNA (no annual filing). Fiscal periods ending between 2025-10-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (SPRB: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in SPRB on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on SPRB in the last 180 days.
Upstream: SEC EDGAR filings for SPRB
Kresmion, "SPRUCE BIOSCIENCES, INC. (SPRB) institutional holdings and SEC filings", data as of 2026-11-15, https://kresmion.com/research/SPRB. Upstream data: SEC EDGAR filings for SPRB.
Link to this data (HTML):
<a href="https://kresmion.com/research/SPRB">SPRUCE BIOSCIENCES, INC. (SPRB) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow SPRB on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to SPRB for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.